$172 Million is the total value of Euclidean Capital LLC's 11 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 36.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PMVP | PMV PHARMACEUTICALS INC | $48,654,000 | -9.9% | 2,336,909 | 0.0% | 28.27% | -7.9% | |
| ME | New | 23ANDME HOLDING CO | $39,231,000 | – | 10,243,122 | +100.0% | 22.80% | – |
| FHTX | FOGHORN THERAPEUTICS INC | $19,209,000 | -33.4% | 1,261,261 | 0.0% | 11.16% | -31.9% | |
| ALEC | ALECTOR INC | $13,978,000 | -31.0% | 980,894 | 0.0% | 8.12% | -29.5% | |
| NGM | NGM BIOPHARMACEUTICALS INC | $11,387,000 | -13.9% | 746,674 | 0.0% | 6.62% | -12.0% | |
| TENAYA THERAPEUTICS INC | $10,787,000 | -37.8% | 915,705 | 0.0% | 6.27% | -36.5% | ||
| RAPT | RAPT THERAPEUTICS INC | $9,519,000 | -40.1% | 432,900 | 0.0% | 5.53% | -38.8% | |
| COIN | New | COINBASE GLOBAL INC | $8,909,000 | – | 46,922 | +100.0% | 5.18% | – |
| FFBC | FIRST FINL BANCORP OH | $4,001,000 | -5.5% | 173,576 | 0.0% | 2.32% | -3.4% | |
| ORIC | ORIC PHARMACEUTICALS INC | $3,992,000 | -63.7% | 747,550 | 0.0% | 2.32% | -62.9% | |
| Sell | SURROZEN INC | $2,417,000 | -53.3% | 802,963 | -0.0% | 1.40% | -52.2% | |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -40,257 | -100.0% | -0.96% | – |
| MQ | Exit | MARQETA INC | $0 | – | -247,752 | -100.0% | -2.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PMV PHARMACEUTICALS INC | 12 | Q3 2023 | 54.4% |
| FOGHORN THERAPEUTICS INC | 12 | Q3 2023 | 16.4% |
| NGM BIOPHARMACEUTICALS INC | 12 | Q3 2023 | 14.5% |
| ALECTOR INC | 12 | Q3 2023 | 11.5% |
| RAPT THERAPEUTICS INC | 12 | Q3 2023 | 9.7% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 10.0% |
| TENAYA THERAPEUTICS INC | 9 | Q3 2023 | 9.9% |
| FIRST FINL BANCORP OH | 9 | Q4 2022 | 3.9% |
| SURROZEN INC | 9 | Q3 2023 | 2.9% |
| 23ANDME HOLDING CO | 7 | Q3 2023 | 27.2% |
View Euclidean Capital LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. | February 14, 2022 | 2,336,909 | 5.1% |
View Euclidean Capital LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2023-12-01 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Euclidean Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.